Real-world outcomes for a digital prescription mobile application for adults with irritable bowel syndrome.

Background: Mahana™ IBS is a Food and Drug Administration-cleared prescription mobile application designed to deliver 3 months of gut-directed cognitive behavioral therapy (CBT) to adults ≥22 years old with irritable bowel syndrome (IBS). We assessed whether gut-directed CBT delivered digitally improved outcomes in IBS management.

Methods: We studied users who had a dispensed physician prescription for Mahana™ IBS between August 2021 and August 2023.